1,011
Participants
Start Date
December 1, 2017
Primary Completion Date
January 3, 2020
Study Completion Date
July 26, 2020
Follitropin alfa
GONAL-F dose was fixed for the first 5 stimulation days.
Follitropin delta
REKOVELLE (FE 999049) was fixed throughout the stimulation period.
Beijing Obstetrics and Gynecology Hospital,Capital Medical University, Beijing
Medical Center for Human Reproduction, Peking University Third Hospital, Beijing
Peking University First Hospital, Beijing
West China Second University Hospital of Sichuan University, Chengdu
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou
The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou
The First Affiliated Hospital of An'hui Medical University, Hefei
Jiangsu Province Hospital, Nanjing
ShengJing Hospital of China Medical University, Shenyang
Peking University Shenzhen Hospital, Shenzhen
Tianjin Central Hospital of Gynaecology and Obstetrics, Tianjin
Tianjin Medical University General Hospital, Tianjin
Renmin Hospital of Wuhan University, Wuhan
Tongji Hospital,Tongji Medical College, Huazhong University of Science & Technology, Wuhan
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Seoul National University Bundang Hospital, Seongnam-si
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Seoul National University Hospital, Seoul
Taichung Veterans General Hospital, Taichung
National Taiwan University Hospital, Taipei
Taipei Medical University Hospital, Taipei
Chang Gung Memorial Hospital, Taoyuan District
National Center for Assisted Reproductive Technology, Hanoi
My Duc Hospital, Ho Chi Minh City
Lead Sponsor
Ferring Pharmaceuticals
INDUSTRY